ALPHA TAU MEDICAL LTDDRTS
ASignal's systematic analysis rates DRTS as Neutral.
Reflects the latest available analysis · analyzed Sep 17, 2026
The case on DRTS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $100.64M in total cash
- Low debt-to-equity ratio of 0.34x indicating conservative leverage
- High liquidity with current ratio of 11.09x
- RSI near neutral at 48.72, suggesting no strong overbought or oversold pressure
- Negative return on equity (-141.68%) indicating severe profitability issues
- Negative free cash flow of $-20.26M
- Negative operating cash flow of $-12.81M
- Negative forward P/E and EV/EBITDA multiples suggest unprofitability
- Zero gross, operating, and net margins
- No Reddit mentions, indicating low retail investor interest
See the full verdict on DRTS
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes DRTS
Most investors never get a second opinion, let alone several. ASignal runs DRTS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.